ZYG11B

Across TCGA pan-cancer cohorts, ZYG11B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZYG11B data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZYG11B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZYG11B expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

HNSC, UCEC, and OV are the cancer types where ZYG11B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.163	0.824	.008	26	view →
UCEC	DFS	Tertile	All	0.782	0.978	.006	26	view →
OV	DFS	Quartile	All	0.500	0.896	.028	16	view →
CCRCC	DFS	Tertile	IV	0.213	0.887	.024	10	view →
GBM	OS	Tertile	All	0.248	0.569	.033	4	view →
PDAC	OS	Quartile	All	0.303	0.471	.036	1	view →
LSCC	OS	Median	All	0.860	0.715	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZYG11B–HNSC (OS)

Open the HNSC breakdown →